For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Banyan Biomarkers, Inc.

USPTO Granted Patents = 15

% Expired Patents = 13.3

CIPO Patents = 3

EPO Patents = 6

Trademarks = 5

Forward Citations = 168

Loading Chart...

Loading Chart...

17 inventors (with patents filed for the assignee):

Kevin Ka-Wang Wang (9 out of 11 patents)

Monika Oli (9 out of 10 patents)

Ronald L Hayes (9 out of 14 patents)

4. Ming-Cheng Liu (6 out of 6 patents)

5. Zhiqun Zhang (4 out of 24 patents)

6. Ka-Wang (Kevin) Wang (3 out of 6 patents)

7. Ming Chen Liu (3 out of 4 patents)

8. Michael Catania (2 out of 2 patents)

9. Andrew K Ottens (2 out of 2 patents)

10. Stanislav Igorevich Svetlov (2 out of 7 patents)

11. Uwe R Mueller (2 out of 2 patents)

12. Alvin Wang (1 out of 2 patents)

13. Victor Prima (1 out of 2 patents)

14. Gabriel Molina (1 out of 2 patents)

15. Jitendra Ramanlal Dave (1 out of 3 patents)

15 patents: Sort by Forward Citations

1. 12601749 - Biomarker detection process and assay of neurological condition (2026-04-14),

2. 12077601 - Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods (2024-09-03),

3. 11994522 - Biomarker detection process and assay of neurological condition (2024-05-28),

4. 11221342 - Neural proteins as biomarkers for nervous system injury and other neural disorders (2022-01-11),

5. 11078298 - Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods (2021-08-03),

6. 10330689 - Neural proteins as biomarkers for nervous system injury and other neural disorders (2019-06-25),

7. 10041959 - Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury (2018-08-07),

8. 9810698 - Neural proteins as biomarkers for nervous system injury and other neural disorders (2017-11-07),

9. 9682132 - Compositions and methods relating to argininosucccinate synthetase (2017-06-20),

10. 9664694 - Neural proteins as biomarkers for nervous system injury and other neural disorders (2017-05-30),

11. 8557526 - Synaptotagmin and collapsin response mediator protein as biomarkers for traumatic brain injury (2013-10-15),

12. 8492107 - Neural proteins as biomarkers for nervous system injury and other neural disorders (2013-07-23),

13. 7645584 - Biomarkers of liver injury (2010-01-12),

14. 7456027 - Proteolytic biomarkers for traumatic injury to the nervous system (2008-11-25),

15. 7396654 - Neural proteins as biomarkers for traumatic brain injury (2008-07-08),

Company Overview

Banyan Biomarkers, Inc. is a biotechnology company based in San Diego, California, specializing in the development of innovative diagnostic solutions for brain injuries. The company focuses on advancing the understanding of traumatic brain injury (TBI) through its proprietary biomarker technologies. Banyan's research aims to improve patient outcomes by providing rapid and accurate assessments, thereby facilitating timely medical interventions. The organization is committed to enhancing clinical decision-making in the field of neurology.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

15 Patents

#375 in San Diego, CA

#5,031 in California

#21,068 in US

#39,959 in the World

San Diego, CA, United States of America

Banyan Biomarkers, Inc.

Forward Citations = 168

17 inventors:

Kevin Ka-Wang Wang (9 out of 11 patents)

Monika Oli (9 out of 10 patents)

Ronald L Hayes (9 out of 14 patents)

4. Ming-Cheng Liu (6 out of 6 patents)

5. Zhiqun Zhang (4 out of 24 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Banyan Biomarkers, Inc.. Retrieved from https://idiyas.com/company/banyan-biomarkers

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…